2024-03-19 19:08:05 ET
Relmada Therapeutics, Inc. (RLMD)
Q4 2023 Earnings Conference Call
March 19, 2024, 04:30 PM ET
Company Participants
Tim McCarthy - IR, Advisors
Sergio Traversa - CEO
Maged Shenouda - CFO
Conference Call Participants
Basma Radwan - Leerink Partners
Uy Ear - Mizuho
Andrew Tsai - Jefferies
Andrea Tan - Goldman Sachs
Presentation
Operator
Good afternoon, ladies and gentlemen, and welcome to the Relmada Therapeutics Inc. Fourth Quarter and Full Year 2023 Results Call. At this time, all lines are in a listen-only mode. Following the presentation, we will conduct a question-and-answer session. [Operator Instructions] This call is being recorded on Tuesday, March 19, 2024.
I would now like to turn the conference over to Mr. Tim McCarthy. Thank you. Please go ahead.
Tim McCarthy
Thank you, operator, and thank you all for joining us this afternoon. With me on today's call are Chief Executive Officer, Sergio Traversa and Chief Financial Officer, Maged Shenouda. This afternoon, Relmada issued a press release, providing a business update, announcing financial results, for the three and 12 months ended December 31, 2023.
Please note that certain information discussed on the call today, is covered under the Safe Harbor provisions, of the Private Securities Litigation Reform Act. We caution listeners that during this call, Relmada's management team will be making forward-looking statements. Actual results could differ materially, from those stated, or implied by these forward-looking statements, due to risks and uncertainties associated with the company's business....
Read the full article on Seeking Alpha
For further details see:
Relmada Therapeutics, Inc. (RLMD) Q4 2023 Earnings Call Transcript